Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Introns × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 22 Genitourinary 8 Gastrointestinal 6 Other hematologic neoplasm 4 Plasma cell 3 Sarcoma 2 Lymphoid 2 Breast 2 NET 1 Gynecologic 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 29 Everolimus 17 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 10 Temozolomide 9 Nivolumab 9 Capecitabine 9 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 lanreotide 7 Positron Emission Tomography Computed Tomography 7 Somatostatin 6 Octreotide 6 90Y-octreotide, DOTA-Tyr(3)- 6 pembrolizumab 5 cabozantinib 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 3-Iodobenzylguanidine 5 pasireotide 4 avelumab 4 Ipilimumab 4 Ga(III)-DOTATOC 4 Carboplatin 4 Al18F-NOTA-octreotide 4 telotristat ethyl 3 surufatinib 3 fluorodopa F 18 3 copper dotatate CU-64 3 Surveys and Questionnaires 3 Single Photon Emission Computed Tomography Computed Tomography 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡